FDA D.I.S.C.O.: FDA approval of cabozantinib for hepatocellular carcinoma
FDA medical oncologists discuss the January 14, 2019, approval of cabozantinib for patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 28, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA D.I.S.C.O.: Avelumab in Merkel Cell Carcinoma Transcript
FDA D.I.S.C.O.: Avelumab in Merkel Cell Carcinoma FDA medical oncologists discuss the agency ’s March 23, 2017, approval of avelumab the treatment of patients 12 years and older with metastatic Merkel cell carcinoma. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 28, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Radiation/immunotherapy combo shows promise for recurrent/metastatic head and neck cancers
(American Society for Radiation Oncology) A new phase II trial finds that a combination of radiation therapy and immunotherapy led to encouraging survival outcomes and acceptable toxicity for patients with locally advanced head and neck squamous cell carcinoma (HNSCC). The combination of radiation and pembrolizumab may offer a new treatment option for patients who are ineligible for cisplatin chemotherapy, part of standard treatment for the disease. Findings will be presented at the 2020 Multidisciplinary Head and Neck Cancers Symposium. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 27, 2020 Category: Cancer & Oncology Source Type: news

Findings Establish PT2385 as a Highly Specific HIF-2 Inhibitor for Patients with Clear Cell RCC
The findings reported in this study demonstrated a core dependency on HIF-2 in metastatic clear cell renal cell carcinoma and established PT2385 as a highly specific HIF-2 inhibitor. (Source: CancerNetwork)
Source: CancerNetwork - February 27, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Liver Transplantation for Hepatocellular Carcinoma Liver Transplantation for Hepatocellular Carcinoma
This article presents a comprehensive review of current knowledge regarding the posttransplant management of patients with hepatocellular carcinoma.American Journal of Transplantation (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 26, 2020 Category: Consumer Health News Tags: Transplantation Journal Article Source Type: news

FDA D.I.S.C.O.: FDA approval of cemiplimab-rwlc for cutaneous squamous cell carcinoma
FDA medical oncologists discuss the September 28, 2018, approval of cemiplimab-rwlc for the treatment of select patients with cutaneous squamous cell carcinoma. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 25, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Banning Indoor Tanning Devices Could Save Lives and Money Banning Indoor Tanning Devices Could Save Lives and Money
Banning indoor tanning devices outright in the United States, Canada, and Europe could prevent as many as 448,000 melanomas and 9.7 million keratinocyte carcinomas,   according to a recent study.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 21, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Clinical trial exposes deadly kidney cancer's Achilles' heel
(UT Southwestern Medical Center) An experimental drug already shown to be safe and help some patients with clear cell renal cell carcinoma, a deadly form of kidney cancer, effectively disables its molecular target. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 20, 2020 Category: Cancer & Oncology Source Type: news

From obesity to liver cancer: Can we prevent the worst?
(Universit é de Gen è ve) Hepatocellular carcinoma, a liver cancer linked to the presence of fat in the liver, is one of the leading causes of cancer death worldwide. Scientists (UNIGE) have discovered a protein involved in the progression of a " fatty liver " towards cancer. This protein could allow early detection of the risk of developing liver cancer and open the way to new targeted therapies. These results highlight the close links between our diet and cancer development. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 19, 2020 Category: Cancer & Oncology Source Type: news

Neoadjuvant Imatinib for an Uncommon Breast Malignancy Neoadjuvant Imatinib for an Uncommon Breast Malignancy
This case highlights the differentiation of dermatofibrosarcoma protuberans from metaplastic breast carcinoma and other spindle cell lesions, as well as the use of imatinib as neoadjuvant treatment.Journal of Medical Case Reports (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - February 18, 2020 Category: Surgery Tags: Family Medicine/Primary Care Journal Article Source Type: news

FDA Grants 2 Fast Track Designations for ALX148
The FDA granted 2 Fast Track designations for ALX148 for the first-line treatment of patients with head and neck squamous cell carcinoma, and for the second-line treatment of patients with HER2-positive gastric or gastroesophageal junction carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - February 18, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

' Incredible' Results With Kidney Cancer Agent With Nobel Ties'Incredible' Results With Kidney Cancer Agent With Nobel Ties
Once thought to be"undruggable," a target in renal cell carcinoma now has a drug aimed at it, and initial results from a small clinical trial are promising.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 18, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Functional proteomics interrogation of the kinome identifies MRCKA as a therapeutic target in high-grade serous ovarian carcinoma
High-grade serous ovarian carcinoma (HGSOC) is the most lethal gynecological cancer with few effective, targeted therapies. HGSOC tumors exhibit genomic instability with frequent alterations in the protein kinome; however, only a small fraction of the kinome has been therapeutically targeted in HGSOC. Using multiplexed inhibitor beads and mass spectrometry, we mapped the kinome landscape of HGSOC tumors from patients and patient-derived xenograft models. The data revealed a prevalent signature consisting of established HGSOC driver kinases, as well as several kinases previously unexplored in HGSOC. Loss-of-function analysi...
Source: Signal Transduction Knowledge Environment - February 18, 2020 Category: Science Authors: Kurimchak, A. M., Herrera-Montavez, C., Brown, J., Johnson, K. J., Sodi, V., Srivastava, N., Kumar, V., Deihimi, S., OBrien, S., Peri, S., Mantia-Smaldone, G. M., Jain, A., Winters, R. M., Cai, K. Q., Chernoff, J., Connolly, D. C., Duncan, J. S. Tags: STKE Research Articles Source Type: news

Staging Guidelines May be Missing Biomarkers that Affect Outcomes in OPSCC
Researchers suggested that the 2017 classifications do not currently allow for uniform stratification and proper outcome prognostication for surgically treated patients with p16-positive oropharyngeal squamous cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - February 17, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Hepatocellular Carcinoma: 5 Things to Know Hepatocellular Carcinoma: 5 Things to Know
Get up to speed on the latest data surrounding the most common form of liver cancer.Medscape Gastroenterology (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - February 14, 2020 Category: Surgery Tags: Gastroenterology Commentary Source Type: news

China National Medical Products Administration grants approval of Roche ’s Tecentriq in combination with chemotherapy as first-line treatment of people with extensive-stage small cell lung cancer
Basel, 14 February 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that China National Medical Products Administration (NMPA) has approved Tecentriq® (atezolizumab) in combination with chemotherapy (carboplatin and etoposide) for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).“Small cell lung cancer is an area of major unmet need in China and one that has seen limited advances until now,” said Levi Garraway, M.D., Ph.D., Chief Medical Officer and Head of Global Product Development. “This approval makes Tecentriq the first cancer immunotherapy...
Source: Roche Media News - February 14, 2020 Category: Pharmaceuticals Source Type: news

China National Medical Products Administration grants approval of Roche ’s Tecentriq in combination with chemotherapy as first-line treatment of people with extensive-stage small cell lung cancer
Basel, 14 February 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that China National Medical Products Administration (NMPA) has approved Tecentriq® (atezolizumab) in combination with chemotherapy (carboplatin and etoposide) for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).“Small cell lung cancer is an area of major unmet need in China and one that has seen limited advances until now,” said Levi Garraway, M.D., Ph.D., Chief Medical Officer and Head of Global Product Development. “This approval makes Tecentriq the first cancer immunotherapy...
Source: Roche Investor Update - February 14, 2020 Category: Pharmaceuticals Source Type: news

Patient-Reported Outcomes Show Newer Drug Combinations Maintain Quality of Life Longer Than Current Standard-of-Care Treatments
Multiple studies showed improved patient outcomes and increased quality of life (QOL) among various treatments that previously demonstrated clinical benefits. These patient-centric findings, along with a promising new combination therapy for patients with advanced hepatocellular carcinoma (HCC) highlight some of the latest research to come out of the 2020 Gastrointestinal Cancers Symposium, held January 23-25, in San Francisco, California. (Source: CancerNetwork)
Source: CancerNetwork - February 13, 2020 Category: Cancer & Oncology Authors: Kevin Wright Source Type: news

FDA Approves Pembrolizumab for BCG-Unresponsive NMIBC
The FDA   approved pembrolizumab (Keytruda) for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or chose to not undergo cystectomy. (Source: CancerNetwork)
Source: CancerNetwork - February 13, 2020 Category: Cancer & Oncology Authors: Kevin Wright Source Type: news

Novel targeted drug shows promise in advanced kidney cancer
(Dana-Farber Cancer Institute) Scientists report promising activity of a novel drug that targets a key molecular driver of clear cell renal cell carcinoma (ccRCC) in patients with metastatic disease. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 13, 2020 Category: Cancer & Oncology Source Type: news

Adding Ilixadencel Improved Outcomes in Metastatic RCC Adding Ilixadencel Improved Outcomes in Metastatic RCC
Combining intratumoral injections of ilixadencel with sunitinib improved responses in patients with newly diagnosed synchronous metastatic renal cell carcinoma in the phase 2 MERECA trial.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 11, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Many Patients With NAFLD Should Be Screened for Liver Cancer, Experts Say Many Patients With NAFLD Should Be Screened for Liver Cancer, Experts Say
Screening and surveillance for hepatocellular carcinoma (HCC) is important in many patients with nonalcoholic fatty liver disease (NAFLD), according to an expert panel of the American Gastroenterological Association (AGA).Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - February 11, 2020 Category: Pathology Tags: Gastroenterology News Source Type: news

Renal Function Change Found to be a Prognostic Factor for Cancer Specific Survival in RCC
The aim of this Chinese study was to evaluate the influencing factors of perioperative renal function change and their relationship with prognosis in patients with renal cell carcinoma and tumor thrombus after nephrectomy and thrombectomy. (Source: CancerNetwork)
Source: CancerNetwork - February 9, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Roche to present new data on Tecentriq in combination with Avastin that shows improvement in overall survival for Chinese patients with the most common form of liver cancer
Basel, 7 February 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that additional data will be presented from a cohort of Chinese patients in the Phase III IMbrave150 study that evaluated Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab) as a treatment for people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy. Data from 194 Chinese patients who took part in the IMbrave150 study were consistent with the global results, that showed a statistically significant and clinically meaningful improvement in overall survival (OS) and progression-free...
Source: Roche Investor Update - February 7, 2020 Category: Pharmaceuticals Source Type: news

Gaps in cure rate appear linked to race and insurance status for common HPV-related cancer
(National Comprehensive Cancer Network) Largest population-based analysis to date on outcomes for HPV-positive oropharyngeal squamous cell carcinoma of the head and neck (SCCHN) finds significant racial and socioeconomic disparities, according to new research in JNCCN-Journal of the National Comprehensive Cancer Network. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 6, 2020 Category: Cancer & Oncology Source Type: news

Nonalcoholic Liver Disease'an Epidemic of the 21st Century'Nonalcoholic Liver Disease'an Epidemic of the 21st Century '
Can trigger a cascade of reactions, leading to liver cirrhosis, hepatocellular carcinoma, and liver failure, explains an expert.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - February 5, 2020 Category: Internal Medicine Tags: Diabetes & Endocrinology News Source Type: news

SIR highlights use of percutaneous ablation for RCC
Some patients with renal cell carcinoma (RCC) can be effectively treated nonsurgically...Read more on AuntMinnie.comRelated Reading: SIR aims for more awareness of interventional radiology SIR taps Findeiss as new president SIR: Virtual reality beats fluoroscopy for catheter placement SIR: 'OK, Google -- scrub up!' SIR: Stroke treatment training program improves outcomes (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - February 5, 2020 Category: Radiology Source Type: news

UArizona receives $6.9m grant to study prevention of non-melanoma skin cancer
(University of Arizona Health Sciences) Skin cancer is the most common malignancy worldwide, and one in three new cancers diagnosed is a form of skin cancer. In response, a team of researchers at the University of Arizona Cancer Center is developing new strategies to prevent and reduce the risk of squamous cell carcinoma, the second most-common form of non-melanoma skin cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 5, 2020 Category: Cancer & Oncology Source Type: news

Scientists find RNA affecting skin cancer progression
(University of Turku) Researchers at the University of Turku, Turku University Central Hospital, and Western Cancer Center (FICAN West) have discovered a new RNA molecule, PRECSIT, which regulates the growth and invasion of squamous cell carcinoma of the skin. In the future, PRECSIT could potentially serve as a new marker for the detection of rapidly advancing or spreading squamous cell carcinoma and as a target for new therapies. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 4, 2020 Category: Cancer & Oncology Source Type: news

Clostridium perfringens enterotoxin induces claudin-4 to activate YAP in oral squamous cell
(Impact Journals LLC) Oncotarget Volume 11, Issue 4: Treatment of human oral squamous cell carcinoma cell lines HSC3 and HSC4 with Clostridium perfringens enterotoxin, induced CLDN4 nuclear translocation to enhance epithelial-mesenchymal transition, stemness, cell proliferation, and invasive ability. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 4, 2020 Category: Cancer & Oncology Source Type: news

Janssen to Highlight Depth of Solid Tumor Portfolio at ASCO GU
RARITAN, N.J., February 3, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today multiple data presentations from a robust solid tumor portfolio that will be featured at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place February 13-15 in San Francisco. Company-sponsored data presentations will include clinical results for ERLEADA® (apalutamide) and niraparib in prostate cancer; and BALVERSA™ (erdafitinib) in bladder cancer. “We are committed to improving outcomes in patients with prostate and bladder cancer where high unmet...
Source: Johnson and Johnson - February 3, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Liver Transplant for Hepatocellular Carcinoma in the U.S. Liver Transplant for Hepatocellular Carcinoma in the U.S.
How have the patterns and outcomes for HCC-related liver transplants evolved over the last thirty years? A new study examines the trends.American Journal of Transplantation (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - February 3, 2020 Category: Surgery Tags: Transplantation Journal Article Source Type: news

QoL Extended With Atezolizumab & #43; Bevacizumab in Liver Cancer
WEDNESDAY, Jan. 29, 2020 -- For patients with unresectable hepatocellular carcinoma, the combination of atezolizumab and bevacizumab is associated with longer time to deterioration of patient-reported quality of life (QOL); and decline in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 29, 2020 Category: Pharmaceuticals Source Type: news

Effectiveness of DAA Treatment for HCV in Patients With HCC Effectiveness of DAA Treatment for HCV in Patients With HCC
Is virologic reponse to direct-acting antivirals as robust in HCV patients with hepatocellular carcinoma as in those without?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 29, 2020 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Biopsy of Pulmonary Large Cell Neuroendocrine Carcinoma Biopsy of Pulmonary Large Cell Neuroendocrine Carcinoma
Via a semiquantitative approach, the authors present biopsy criteria for differentiating pulmonary large cell neuroendocrine carcinoma from non-small cell lung carcinoma.American Journal of Clinical Pathology (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - January 28, 2020 Category: Pathology Tags: Pathology & Lab Medicine Journal Article Source Type: news

New Therapeutic Interventions for Advanced HCC New Therapeutic Interventions for Advanced HCC
This article reviews the latest clinical trials on current and emerging first-line and second-line therapeutic options available for patients with advanced hepatocellular carcinoma.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 27, 2020 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

LMR for Prognosis of Radioiodine-Refractory Thyroid Cancer LMR for Prognosis of Radioiodine-Refractory Thyroid Cancer
Find out how the lymphocyte-to-monocyte ratio may aid in the prognosis of patients with progressive radioiodine-refractory differentiated thyroid carcinoma.Clinical Endocrinology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 27, 2020 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

New Drug Combo Potentially Practice Changing in Advanced HCC New Drug Combo Potentially Practice Changing in Advanced HCC
Atezolizumab plus bevacizumab was superior to sorafenib for maintaining quality of life in patients with unresectable hepatocellular carcinoma (HCC).Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 27, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Roche submits supplemental Biologics License Application to the FDA for Tecentriq in combination with Avastin for the most common form of liver cancer
Roche today announced the completion of a supplemental Biologics License Application (sBLA) submission to the US Food and Drug Administration (FDA) for Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab), for the treatment of people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy. (Source: Roche Media News)
Source: Roche Media News - January 27, 2020 Category: Pharmaceuticals Source Type: news

Roche submits supplemental Biologics License Application to the FDA for Tecentriq in combination with Avastin for the most common form of liver cancer
      ·Application is being reviewed under FDA ’s Real-Time Oncology Review pilot programmeBasel, 27 January 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the completion of a supplemental Biologics License Application (sBLA) submission to the US Food and Drug Administration (FDA) for Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab), for the treatment of people with unresectab le hepatocellular carcinoma (HCC) who have not received prior systemic therapy. The FDA is reviewing the application under the Real-Time Oncology Review pilot programme, wh...
Source: Roche Investor Update - January 27, 2020 Category: Pharmaceuticals Source Type: news

Genentech Submits sBLA for Atezolizumab Plus Bevacizumab Combo to Treat Unresectable HCC
The company ’s application is based on results from the phase III IMbrave150 study of the regimen for the treatment of patients with unresectable hepatocellular carcinoma who have not received prior systemic therapy. (Source: CancerNetwork)
Source: CancerNetwork - January 27, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

The virome of HPV-positive tonsil squamous cell carcinoma and neck metastasis
(Impact Journals LLC) In this prospective study, a pan-pathogen microarray was used to determine the virome of early stage, p16-positive OPSCC and neck metastasis treated with transoral robotic surgery and neck dissection. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 27, 2020 Category: Cancer & Oncology Source Type: news

HPV-Positive Sinonasal Squamous Cell Carcinoma May Be Associated with Improved OS
This research indicated that routine HPV testing may be necessary for patients with squamous cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - January 24, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

GW Cancer Center expands clinical trial offerings for cutaneous squamous cell carcinoma
(George Washington University) The Cutaneous Oncology Program at the GW Cancer Center was selected as the first global site for a clinical trial for patients with high-risk cutaneous squamous cell carcinoma. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 22, 2020 Category: Cancer & Oncology Source Type: news

Lower Hepatoma Risk With Earlier ALT Normalization During HBV Treatment Lower Hepatoma Risk With Earlier ALT Normalization During HBV Treatment
Earlier normalization of alanine aminotransferase (ALT) levels during treatment of chronic hepatitis B is independently associated with a reduced risk of hepatocellular carcinoma (HCC), researchers from South Korea report.Reuters Health Information (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - January 21, 2020 Category: Transplant Surgery Tags: Hematology-Oncology News Source Type: news

Imfinzi and tremelimumab granted Orphan Drug Designation in the US for liver cancer
AstraZeneca's Imfinzi (durvalumab) and tremelimumab, an anti-CTLA4 antibody and potential new medicine, have both been granted Orphan Drug Designation (ODD) in the US for the treatment of hepatocellular carcinoma (HCC), the most common type of liver cancer. (Source: World Pharma News)
Source: World Pharma News - January 20, 2020 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

Head/neck cancer diagnosis, time to treatment after ACA Medicaid expansions
(JAMA Network) Researchers for this observational study examined the association between the expansion of Medicaid coverage in some states after the Patient Protection and Affordable Care Act (ACA) was passed and the diagnosis and treatment of patients with head and neck squamous cell carcinoma (HNSCC). The analysis included nearly 91,000 adults with newly diagnosed HNSCC who were identified from the National Cancer Database. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 16, 2020 Category: Cancer & Oncology Source Type: news

Disease profile in England: Incidence, mortality, stage and survival for ovary, fallopian tube and primary peritoneal carcinomas
This report provides a detailed insight into the status of ovarian cancer in England. It is the first report from the Cancer Audit Feasibility Pilot project which runs for two years and includes details of disease incidence, mortality and survival. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - January 10, 2020 Category: Consumer Health News Source Type: news

FDA Approves Pembrolizumab for High-Risk Bladder Cancer FDA Approves Pembrolizumab for High-Risk Bladder Cancer
Pembrolizumab is now approved for patients with bacillus Calmette-Guerin -unresponsive, high-risk, non-muscle invasive bladder cancer with carcinoma in situ.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 8, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

FDA Approves Pembrolizumab for Treatment of Certain Patients with NMIBC
The FDA approved pembrolizumab for the treatment of patients with BCG –unresponsive, high-risk, non-muscle invasive bladder cancer with carcinoma in-situ with or without papillary tumors who are ineligible for or chose to not undergo cystectomy. (Source: CancerNetwork)
Source: CancerNetwork - January 8, 2020 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news